TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · IEX Real-Time Price · USD
7.31
+0.02 (0.27%)
Apr 26, 2024, 12:47 PM EDT - Market open
TScan Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for TScan Therapeutics stock have an average target of 11.33, with a low estimate of 9.00 and a high estimate of 15. The average target predicts an increase of 54.99% from the current stock price of 7.31.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TCRX stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $10 | Buy | Reiterates | $10 | +36.80% | Apr 23, 2024 |
| Barclays | Barclays | Buy Maintains $7 → $9 | Buy | Maintains | $7 → $9 | +23.12% | Mar 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +105.20% | Mar 7, 2024 |
| Wedbush | Wedbush | Buy Reiterates $9 | Buy | Reiterates | $9 | +23.12% | Feb 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +105.20% | Aug 14, 2023 |
Financial Forecast
Revenue This Year
16.84M
from 21.05M
Decreased by -19.98%
Revenue Next Year
11.60M
from 16.84M
Decreased by -31.14%
EPS This Year
-1.07
from -1.36
EPS Next Year
-1.13
from -1.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 23.6M | 23.1M | 36.5M | 64.2M | 112.3M |
| Avg | 16.8M | 11.6M | 9.7M | 34.6M | 54.6M |
| Low | 9.8M | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 12.2% | 37.0% | 215.0% | 562.9% | 224.4% |
| Avg | -20.0% | -31.1% | -16.5% | 257.3% | 57.6% |
| Low | -53.4% | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.05 | -1.00 | -1.01 | -0.57 | -0.41 |
| Avg | -1.07 | -1.13 | -1.16 | -1.00 | -1.20 |
| Low | -1.09 | -1.16 | -1.35 | -1.71 | -1.93 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.